Replies to post #252199 on Anavex Life Sciences Corp (AVXL)

[powerwalker]

So, Doc, you or others may have answered this question before, but it might be worthwhile to re-visit.

While Anavex's P2b trial for Alzheimer's is 48 weeks, its P2 PDD trial is only 14 weeks. Why the shorter time period for PDD? Why is it expected that the PDD participants will respond more quickly?

TIA, Doc and/or other responder(s).


ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES!!!

[georgejjl]

Anavex 2-73 and/or Anavex 3-71 for the treatment of Parkinson's disease

Sigma-1 Receptor Deficiency Reduces MPTP-induced Parkinsonism and Death of Dopaminergic Neurons

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650739/

Development and Characterization of an Inducible Dicer Conditional Knockout Mouse Model of Parkinson's Disease: Validation of the Antiparkinsonian Effects of a sigma-1 Receptor Agonist and Dihydromyricetin

https://pubmed.ncbi.nlm.nih.gov/32112040/?from_term=%22sigma+1%22+parkinson%27s+motor&from_sort=date&from_size=200&from_pos=1

Chaperone Sigma1R Mediates the Neuroprotective Action of Afobazole in the 6-OHDA Model of Parkinson's Disease

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863824/

Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554374/

Trial of Dextromethorphan/Quinidine to Treat Levodopa-Induced Dyskinesia in Parkinson's Disease

https://onlinelibrary.wiley.com/doi/abs/10.1002/mds.26976

Good luck and GOD bless,

[frrol]

Interesting. That would explain why it's not a primary outcome in our trial, and I suppose based on your explanation that it was included as a secondary outcome just to check that motor skills do not degrade from baseline. You have drug trial experience, so what do you think? I can think of no other reason why it would be included as an "outcome" at all, given that the company surely (?) would anticipate the negative cholinergic implications of 2-73 in PD motor activity.

It's always good to point out that we're talking about experimental compounds for complex diseases. Not magic beans.

[Investor2014]

Are there no parallels between motor functions in Rett and PD?

Administration of the drug to younger and older adult mice resulted in improvement in multiple motor, sensory, and autonomic phenotypes of relevance to RTT

ANAVEX®2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome